Pharsight

Recorlev patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098877 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(1 year, 9 months from now)

US10835530 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(1 year, 9 months from now)

US10517868 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(1 year, 9 months from now)

US9918984 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(1 year, 9 months from now)

US11478471 STRONGBRIDGE NA
Jan, 2026

(1 year, 9 months from now)

US11278547 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(15 years from now)

US11020393 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(15 years from now)

Recorlev is owned by Strongbridge.

Recorlev contains Levoketoconazole.

Recorlev has a total of 7 drug patents out of which 0 drug patents have expired.

Recorlev was authorised for market use on 30 December, 2021.

Recorlev is available in tablet;oral dosage forms.

Recorlev can be used as treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative, during levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage of metformin as needed.

The generics of Recorlev are possible to be released after 02 March, 2040.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 30, 2028

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Market Authorisation Date: 30 December, 2021

Treatment: Treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative; During levoketoconazole dosage titration for the treatment of ...

Dosage: TABLET;ORAL

More Information on Dosage

RECORLEV family patents

Family Patents